160 related articles for article (PubMed ID: 20097592)
1. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment.
Bray MG; Poulain C; Dougados M; Gossec L
Joint Bone Spine; 2010 Mar; 77(2):135-41. PubMed ID: 20097592
[TBL] [Abstract][Full Text] [Related]
2. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
Fresard I; Bridevaux PO; Rochat T; Janssens JP
Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
[TBL] [Abstract][Full Text] [Related]
3. High incidence of intolerance to tuberculosis chemoprophylaxis.
Haroon M; Martin U; Devlin J
Rheumatol Int; 2012 Jan; 32(1):33-7. PubMed ID: 20658233
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Barbeau P; Skidmore B; Alvarez GG
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):557-566. PubMed ID: 29573031
[TBL] [Abstract][Full Text] [Related]
5. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.
Long MW; Snider DE; Farer LS
Am Rev Respir Dis; 1979 Jun; 119(6):879-94. PubMed ID: 110184
[TBL] [Abstract][Full Text] [Related]
6. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
7. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
Gray EL; Goldberg HF
Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
[TBL] [Abstract][Full Text] [Related]
8. Isoniazid-rifampicin induced lipid changes in rats.
Pal R; Rana SV; Vaiphei K; Singh K
Clin Chim Acta; 2008 Mar; 389(1-2):55-60. PubMed ID: 18157944
[TBL] [Abstract][Full Text] [Related]
9. Selected pharmaceutical excipient prevent isoniazid and rifampicin induced hepatotoxicity.
Shih TY; Ho SC; Hsiong CH; Huang TY; Hu OY
Curr Drug Metab; 2013 Jul; 14(6):720-8. PubMed ID: 23701163
[TBL] [Abstract][Full Text] [Related]
10. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
[TBL] [Abstract][Full Text] [Related]
11. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.
Bouazzi OE; Hammi S; Bourkadi JE; Tebaa A; Tanani DS; Soulaymani-Bencheikh R; Badrane N; Bengueddour R
Pan Afr Med J; 2016; 25():167. PubMed ID: 28292129
[TBL] [Abstract][Full Text] [Related]
12. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis.
O'Brien RJ; Long MW; Cross FS; Lyle MA; Snider DE
Pediatrics; 1983 Oct; 72(4):491-9. PubMed ID: 6604257
[TBL] [Abstract][Full Text] [Related]
13. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
Gordin FM; Cohn DL; Matts JP; Chaisson RE; O'Brien RJ; ; ;
Clin Infect Dis; 2004 Aug; 39(4):561-5. PubMed ID: 15356822
[TBL] [Abstract][Full Text] [Related]
14. Reparation of Isoniazid and Rifampicin Combinatorial Therapy-Induced Hepatotoxic Effects by Bacopa monnieri.
Evan Prince S; Udhaya LB; Sunitha PS; Arumugam G
Pharmacology; 2016; 98(1-2):29-34. PubMed ID: 27007136
[TBL] [Abstract][Full Text] [Related]
15. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy.
Li F; Lu J; Cheng J; Wang L; Matsubara T; Csanaky IL; Klaassen CD; Gonzalez FJ; Ma X
Nat Med; 2013 Apr; 19(4):418-20. PubMed ID: 23475203
[TBL] [Abstract][Full Text] [Related]
16. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
[TBL] [Abstract][Full Text] [Related]
17. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
[TBL] [Abstract][Full Text] [Related]
18. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Tedla Z; Nyirenda S; Peeler C; Agizew T; Sibanda T; Motsamai O; Vernon A; Wells CD; Samandari T
Am J Respir Crit Care Med; 2010 Jul; 182(2):278-85. PubMed ID: 20378730
[TBL] [Abstract][Full Text] [Related]
19. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
[TBL] [Abstract][Full Text] [Related]
20. Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents.
Bourré-Tessier J; Arino-Torregrosa M; Choquette D
Clin Rheumatol; 2014 Aug; 33(8):1049-53. PubMed ID: 24554383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
